C. Illig

发表

Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.

S. Meegalla, Hui-Sheng Huang, C. Illig, 2016, Bioorganic & medicinal chemistry letters.

Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.

S. Meegalla, C. Illig, D. Parks, 2011, Journal of medicinal chemistry.

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.

B. Tomczuk, R. DesJarlais, S. Meegalla, 2013, Bioorganic & medicinal chemistry letters.

Nitrone cycloadditions. regiochemistry.

C. Illig, S. Ali, J. Tufariello, 1979 .

Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors.

R. DesJarlais, J. Spurlino, C. Illig, 2002, Bioorganic & medicinal chemistry letters.

Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.

B. Tomczuk, R. DesJarlais, S. Meegalla, 2010, Bioorganic & medicinal chemistry letters.

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

B. Tomczuk, S. Meegalla, C. Illig, 2009, Molecular Cancer Therapeutics.

Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors.

B. Tomczuk, J. Spurlino, C. Illig, 2000, Bioorganic & medicinal chemistry letters.

In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors.

B. Tomczuk, J. Spurlino, C. Illig, 1998, Bioorganic & medicinal chemistry letters.

Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor.

B. Tomczuk, J. Spurlino, C. Illig, 2000, Bioorganic & medicinal chemistry letters.

In vitro Evaluation and Crystallographic Analysis of a New Class of Selective, Non‐Amide‐Based Thrombin Inhibitors.

B. Tomczuk, J. Spurlino, C. Illig, 1998 .

Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.

J. Spurlino, C. Illig, R. Bone, 1998, Journal of medicinal chemistry.

Amidinohydrazones as Guanidine Bioisosteres: Application to a New Class of Potent, Selective and Orally Bioavailable, Non‐amide‐based Small‐Molecule Thrombin Inhibitors.

B. Tomczuk, J. Spurlino, C. Illig, 2000 .

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors.

R. DesJarlais, J. Spurlino, C. Illig, 2001, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.

R. DesJarlais, J. Spurlino, C. Illig, 2001, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.

B. Tomczuk, R. DesJarlais, S. Meegalla, 2008, Bioorganic & medicinal chemistry letters.

Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.

B. Tomczuk, R. DesJarlais, S. Meegalla, 2008, Bioorganic & medicinal chemistry letters.

Stereoselective synthesis of (.+-.)-cyanocycline.

C. Illig, D. Evans, J. Saddler, 1986, Journal of the American Chemical Society.

A novel series of potent and selective small molecule inhibitors of the complement component C1s.

R. DesJarlais, J. Spurlino, C. Illig, 2004, Bioorganic & medicinal chemistry letters.

Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).

B. Tomczuk, R. DesJarlais, S. Meegalla, 2011, Journal of medicinal chemistry.

Structure-based optimization of a potent class of arylamide FMS inhibitors.

Jinsheng Chen, Mark R Player, B. Tomczuk, 2008, Bioorganic & medicinal chemistry letters.

Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.

B. Tomczuk, R. DesJarlais, S. Meegalla, 2008, Bioorganic & medicinal chemistry letters.